Evidence map›Paper›PMID 33779768›Full record

SynthesisEuropean journal of clinical pharmacology2021

The impacts of race and regimens on the efficacy and safety of paclitaxel and platinum combination treatment for patients with advanced non-small cell lung cancer.

Chenyang Zhao, Fengli Wang, Jihan Huang, Yinghua Lv, Fang Yin, Hongxia Liu, Qingshan Zheng, Lujin Li

Abstract readMeta-Analysis
PubMed Publisher
In one paragraph

Synthesis in European journal of clinical pharmacology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.3field-weighted citation impact, top 42% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 2 citations in OpenAlex.

  1. Trial
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 1 institution in 1 country.

Chenyang ZhaoCenter for Drug Clinical Evaluation, Shanghai University of Traditional Chinese Medicine, Shanghai, China.
Fengli WangCenter for Drug Clinical Evaluation, Shanghai University of Traditional Chinese Medicine, Shanghai, China.
Jihan HuangCenter for Drug Clinical Evaluation, Shanghai University of Traditional Chinese Medicine, Shanghai, China.
Yinghua LvCenter for Drug Clinical Evaluation, Shanghai University of Traditional Chinese Medicine, Shanghai, China.
Fang YinCenter for Drug Clinical Evaluation, Shanghai University of Traditional Chinese Medicine, Shanghai, China.
Hongxia LiuCenter for Drug Clinical Evaluation, Shanghai University of Traditional Chinese Medicine, Shanghai, China.
Qingshan ZhengCenter for Drug Clinical Evaluation, Shanghai University of Traditional Chinese Medicine, Shanghai, China. qingshan.zheng@drugchina.net.
Lujin LiCenter for Drug Clinical Evaluation, Shanghai University of Traditional Chinese Medicine, Shanghai, China. lilujin666@163.com.
Shanghai University of Traditional Chinese Medicine · CN

Funding

National Major Science and Technology Projects of China 2017ZX09304003National Major Science and Technology Projects of China 2018ZX09711001-009-011National Major Science and Technology Projects of China 2018ZX09731016National Major Science and Technology Projects of China 2018ZX09734005National Major Science and Technology Projects of China 2018ZX10303501Shanghai S&T Innovation Plan 17401970900
6 · The paper itself

Abstract

purposePaclitaxel-platinum chemotherapy is the first-line treatment for advanced non-small cell lung cancer (NSCLC) patients. This study quantitatively evaluated the factors influencing the efficacy and safety of the paclitaxel-platinum regimen to provide the necessary reference for the development of clinical practice and clinical trials.

methodsA literature search was performed using public databases. The parametric survival function was used to analyze the overall survival (OS) time course of patients treated with the paclitaxel-platinum regimen. The random effects model in the single-arm meta-analysis was used to analyze the objective response rate (ORR) and the incidence of grade 3-4 adverse events (AEs) under the predefined subgroups according to race and the regimen.

resultsA total of 31 studies consisting of 3365 participants were included in the analysis. Race was the most important determinant of efficacy and safety in the paclitaxel-platinum regimen, with the median survival time and ORR in East Asians and non-East Asians being 12.2 months (95% CI: 10.5-14.4 months) and 37% (95% CI: 32-41%) and 8.4 months (95% CI: 6.5-11.0 months) and 28% (95% CI: 25-32%), respectively. The incidence of grade 3-4 AEs such as leukopenia and neutropenia was about three times higher in East Asians compared to non-East Asians.

conclusionsThe efficacy and safety of the paclitaxel-platinum regimen can vary between East Asian and non-East Asian populations and between different treatment schedules. The results of this study can provide a reliable and precise external control for the future evaluation of new treatment options for advanced NSCLC.

Indexed as

Asian PeopleAntineoplastic Combined Chemotherapy ProtocolsCarcinoma, Non-Small-Cell LungDose-Response Relationship, DrugDrug Administration ScheduleHumansLung NeoplasmsMonte Carlo MethodNeoplasm StagingPaclitaxelPlatinumSurvival AnalysisPaclitaxelPlatinumAdvanced NSCLCModeling and simulationOverall survivalPaclitaxelPlatinum

Identifiers

PMID33779768
OpenAlexW3141527622

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.